Strong Performance in Third Quarter 2025
TG Therapeutics, Inc. (NASDAQ: TGTX), dedicated to advancing treatments for B-cell diseases, has released its financial results for the third quarter of 2025.
In this reporting period, the company achieved an impressive total revenue of $161.7 million. This figure includes a remarkable net revenue of $152.9 million from their flagship product, BRIUMVI, in the U.S., marking a significant year-over-year growth rate of 84% compared to the same quarter in the previous year.
Revised 2025 Revenue Targets
Reflecting robust market demand, TG Therapeutics has raised its full-year 2025 revenue guidance for BRIUMVI's U.S. net product revenue to approximately $585 million, up from earlier estimates between $570 million and $575 million. The global revenue target for the same year has also been increased to $600 million.
Leadership Insights
Michael S. Weiss, Chairman and CEO of TG Therapeutics, expressed satisfaction with the third quarter's performance, emphasizing the company's commitment to maintaining a disciplined capital allocation strategy while driving forward its clinical pipeline. Two Phase 3 programs are currently in progress—one focusing on the subcutaneous formulation of ublituximab and another exploring a simplified dosing schedule for BRIUMVI IV.
Key Developments in Clinical Trials
Recently, TG Therapeutics made significant advancements in its research endeavors. During the ECTRIMS annual meeting, key data presentations showcased the long-term efficacy of BRIUMVI in treating relapsing multiple sclerosis (RMS). Noteworthy findings from the ULTIMATE trials highlighted that 89.9% of patients remained free from confirmed disability progression after 6 years of treatment.
Commercialization Updates
BRIUMVI's commercialization continues to extend internationally, with approvals in regions such as Europe, the United Kingdom, Switzerland, Australia, Kuwait, and the UAE, through partnerships with Neuraxpharm.
Pipeline Expansion and Share Repurchase Program
The company has also made strides in its pipeline development. Recently, TG Therapeutics commenced patient enrollment in a Phase 3 pivotal program for subcutaneous ublituximab while successfully completing another Phase 3 trial evaluating a consolidated dosing regimen for the IV formulation.
Moreover, the completion of a $100 million share repurchase program demonstrates the company's confidence in its long-term strategy. They have also authorized a new $100 million share buyback to reinforce this commitment.
Financial Performance Overview
For the three months ended September 30, 2025, TG Therapeutics reported:
- Product revenue of $159.3 million—an increase from $83.3 million year-over-year.
- Total revenue including license and royalty revenues was $161.7 million.
- Research and development expenses totaled approximately $40.9 million, reflecting increased costs associated with advancing clinical pipelines.
- Net income reached $390.9 million, significantly boosted by a non-recurring income tax benefit.
Outlook and Future Directions
As TG Therapeutics moves forward into the fourth quarter, the focus remains on expanding patient awareness of BRIUMVI among healthcare professionals and patients alike. This is pivotal as the company aims to build upon its current momentum, maintaining strong enrollment in ongoing clinical trials while enhancing value for shareholders.
Frequently Asked Questions
What are the key financial results for the third quarter of 2025?
The company reported a total revenue of $161.7 million, with BRIUMVI's U.S. net product revenue at $152.9 million.
What is the new revenue guidance for BRIUMVI for 2025?
TG Therapeutics has raised its U.S. net product revenue target for BRIUMVI to approximately $585 million for the full year 2025.
What recent developments have been made regarding clinical studies?
Key data showcased during the ECTRIMS annual meeting demonstrated favorable long-term efficacy for BRIUMVI in RMS patients.
What are the company’s plans around share repurchases?
TG Therapeutics has completed a $100 million share repurchase program and authorized an additional $100 million program to enhance shareholder value.
What is TG Therapeutics' main product, and what conditions does it treat?
BRIUMVI is TG Therapeutics' main product, indicated for RMS treatment, including relapsing forms of multiple sclerosis.
